Selank: A Calm-Without-Sedation Peptide With a Russian Evidence Base
A plain-English look at Selank, the tuftsin-derived anxiolytic peptide: how it works, what the (largely Russian) research shows, doses studied, and honest limits.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-07-02A tuftsin-derived anxiolytic approved in Russia, with a coherent but geographically narrow, single-lineage evidence base; long-term safety is uncharacterised and there are no large independent Western trials.
A tuftsin-derived peptide with proposed anxiolytic and neuromodulatory actions described mostly in rodents.
Rodent mechanistic work, largely from one research lineage.
Small human trials, mostly within the Russian research base; no large modern placebo-controlled or independent Western trials.
A coherent profile that has not met the bar of large independent trials.
Tolerability in the Russian trials was good, but long-term human safety is essentially uncharacterised and CNS-drug interactions are unstudied in people.
Approved in Russia but with no modern independent development; emerging elsewhere.
Narrow, single-lineage evidence keeps confidence low.
Approved in Russia/CIS only; outside that it is an unapproved research compound, and grey-market intranasal product quality is not guaranteed. FDA Category 2 nomination later withdrawn — not currently in the active Category 2 table, which is not a clearance and leaves the concerns FDA published standing.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A tuftsin-derived anxiolytic peptide, approved in Russia for anxiety/neurasthenia. The evidence is real but geographically narrow — largely one research lineage, mostly rodent for mechanism, with small human trials and no large modern placebo-controlled or independent Western trials.
Safety snapshot
Tolerability in the Russian trials was good, but long-term human safety is essentially uncharacterised; theoretical interactions with GABAergic, opioid and other CNS-active drugs are unstudied in people, and response may be individual.
Regulatory & legality
Approved in Russia/CIS only; outside that it is an unapproved research compound with no FDA or EMA marketing authorisation, and grey-market intranasal product quality is not guaranteed. The FDA has nonetheless assessed it for compounding: it lists Selank acetate (TP-7) — the acetate salt specifically — among bulk substances nominated to Category 2 whose nominations were withdrawn, so it is not currently in the active Category 2 table; a withdrawal is not approval or clearance and the FDA still publishes the concerns it identified.
Where claims can exceed the evidence
An encouraging, coherent profile that has not met the bar of large independent trials; the published claims should be read as preliminary, not settled.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Selank is a synthetic peptide developed in Russia as an anti-anxiety agent that, on paper, does something benzodiazepines struggle with: calm you down without the sedation, the cognitive fog, or the dependence. It has been approved and marketed in Russia since the late 2000s as an intranasal spray for generalised anxiety disorder (GAD) and neurasthenia [8][9].
For self-experimenters, Selank is interesting precisely because it sits in an unusual spot. The evidence is real and reasonably consistent — but it is also geographically narrow. Almost all of it comes from a handful of Russian research institutes, most of the rigorous mechanistic work is in rodents, and the human trials are small and published largely in Russian-language journals. There are no large modern placebo-controlled trials, no independent Western replication, and no FDA or EMA evaluation. This article walks through what is genuinely known, what is plausible, and what is still guesswork.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
DSIP: The "Sleep Peptide" That Never Quite Proved Itself
A clear-eyed look at delta sleep-inducing peptide (DSIP): old, contradictory human data, an unknown mechanism, no modern trials, and why the evidence stays weak.
Melatonin: A Clock-Setter, Not a Sledgehammer
Melatonin is strong evidence for jet lag and circadian disorders but only modest for adult insomnia — timing matters more than dose.
Semax: A Russian Brain Peptide With Strong Animal Data and Thin Human Proof
Semax boosts BDNF and modulates dopamine and serotonin in rodents, but human evidence is small, Russian-only, and mostly stroke-focused — not nootropic.